{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T15:25:35Z","timestamp":1774020335453,"version":"3.50.1"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:00:00Z","timestamp":1763769600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004329","name":"Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Italian Association for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.canlet.2025.218128","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T02:27:32Z","timestamp":1763346452000},"page":"218128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Nanoformulation of a Pin1 inhibitor potentiates the efficacy of liposomal doxorubicin in second-line therapy for ovarian cancer"],"prefix":"10.1016","volume":"637","author":[{"given":"Gloria","family":"Saorin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Mauceri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabella","family":"Caligiuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0481-4226","authenticated-orcid":false,"given":"Urska","family":"Kamensek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0538-7841","authenticated-orcid":false,"given":"Simona","family":"Kranjc Brezar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Corona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0785-5066","authenticated-orcid":false,"given":"Ombretta","family":"Repetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziana","family":"Perin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Grassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5849-0722","authenticated-orcid":false,"given":"Carlotta","family":"Granchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6205-4069","authenticated-orcid":false,"given":"Tiziano","family":"Tuccinardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1418-1928","authenticated-orcid":false,"given":"Maja","family":"Cemazar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Canzonieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Adeel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3400-4363","authenticated-orcid":false,"given":"Flavio","family":"Rizzolio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2025.218128_bib1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2991\/jegh.k.191008.001","article-title":"Current cancer epidemiology","volume":"9","author":"Mattiuzzi","year":"2019","journal-title":"J. Epidemiol. Glob. Health"},{"key":"10.1016\/j.canlet.2025.218128_bib2","series-title":"Cancer Screening","first-page":"431","article-title":"Ovarian cancer","author":"Seltzer","year":"2021"},{"key":"10.1016\/j.canlet.2025.218128_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/metabo10100419","article-title":"Emerging role of metabolomics in ovarian cancer diagnosis","volume":"10","author":"Saorin","year":"2020","journal-title":"Metabolites"},{"key":"10.1016\/j.canlet.2025.218128_bib4","doi-asserted-by":"crossref","first-page":"5031","DOI":"10.21873\/anticanres.11072","article-title":"Non-epithelial ovarian cancer: elucidating uncommon gynaecological malignancies","volume":"36","author":"Boussios","year":"2016","journal-title":"Anticancer Res."},{"key":"10.1016\/j.canlet.2025.218128_bib5","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3390\/ijms20040952","article-title":"High-grade serous ovarian cancer: basic sciences, clinical and therapeutic standpoints","volume":"20","author":"Lisio","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2025.218128_bib6","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1200\/JCO.19.00194","article-title":"Management of platinum-resistant, relapsed epithelial ovarian cancer and new drug perspectives","volume":"37","author":"Pujade-Lauraine","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.218128_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12645-025-00340-3","article-title":"Nanodrug-based modulation of platelet\u2013leukocyte interactions in ovarian cancer: a new frontier in targeted therapy","volume":"16","author":"Naghinezhad","year":"2025","journal-title":"Cancer Nanotechnol."},{"key":"10.1016\/j.canlet.2025.218128_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-024-55801-3","article-title":"Microfluidic production of amiodarone loaded nanoparticles and application in drug repositioning in ovarian cancer","volume":"14","author":"Saorin","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2025.218128_bib9","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-025-00818-7","article-title":"Therapeutic landscape of ovarian cancer: recent advances and emerging therapies","volume":"13","author":"Wang","year":"2025","journal-title":"Biomark. Res."},{"key":"10.1016\/j.canlet.2025.218128_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00094","article-title":"Oncogenic hijacking of the PIN1 signaling network","volume":"9","author":"Zannini","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2025.218128_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.01367","article-title":"PIN1 in cell cycle control and cancer","volume":"9","author":"Cheng","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.canlet.2025.218128_bib12","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1073\/pnas.032404099","article-title":"Loss of Pin1 function in the mouse causes phenotypes resembling cyclin D1-null phenotypes","volume":"99","author":"Liou","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2025.218128_bib13","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/cdd.2011.202","article-title":"Retinoblastoma tumor-suppressor protein phosphorylation and inactivation depend on direct interaction with Pin1","volume":"19","author":"Rizzolio","year":"2012","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.canlet.2025.218128_bib14","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/jcp.24107","article-title":"Dissecting Pin1 and phospho-pRb regulation","volume":"228","author":"Rizzolio","year":"2013","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.canlet.2025.218128_bib15","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/ncb0901-793","article-title":"Pin1 regulates turnover and subcellular localization of \u03b2-catenin by inhibiting its interaction with APC","volume":"3","author":"Ryo","year":"2001","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.canlet.2025.218128_bib16","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/nature01120","article-title":"The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults","volume":"419","author":"Zacchi","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2025.218128_bib17","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1128\/MCB.01455-12","article-title":"Pin1 regulates the dynamics of c-Myc DNA binding to facilitate target gene regulation and oncogenesis","volume":"33","author":"Farrell","year":"2013","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2025.218128_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2023.110940","article-title":"Prolyl isomerase Pin1 promotes autophagy and cancer cell viability through activating FoxO3 signalling","volume":"113","author":"Long","year":"2024","journal-title":"Cell. Signal."},{"key":"10.1016\/j.canlet.2025.218128_bib19","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/cdd.2016.122","article-title":"PIN1 in breast development and cancer: a clinical perspective","volume":"24","author":"Rustighi","year":"2017","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.canlet.2025.218128_bib20","first-page":"6244","article-title":"The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer","volume":"63","author":"Ayala","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2025.218128_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0055355","article-title":"The prolyl isomerase Pin1 acts synergistically with CDK2 to regulate the basal activity of estrogen receptor \u03b1 in breast cancer","volume":"8","author":"Lucchetti","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2025.218128_bib22","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.4161\/cc.21730","article-title":"Androgen receptor serine 81 mediates Pin1 interaction and activity","volume":"11","author":"La Montagna","year":"2012","journal-title":"Cell Cycle"},{"key":"10.1016\/j.canlet.2025.218128_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2018.04.055","article-title":"Liposomal delivery of a Pin1 inhibitor complexed with cyclodextrins as new therapy for high-grade serous ovarian cancer","volume":"281","author":"Russo Spena","year":"2018","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.canlet.2025.218128_bib24","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1038\/sj.emboj.7600323","article-title":"Modeling breast cancer in vivo and ex vivo reveals an essential role of Pin1 in tumorigenesis","volume":"23","author":"Wulf","year":"2004","journal-title":"EMBO J."},{"key":"10.1016\/j.canlet.2025.218128_bib25","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1128\/MCB.26.4.1463-1479.2006","article-title":"Pin1 regulates centrosome duplication, and its overexpression induces centrosome amplification, chromosome instability, and oncogenesis","volume":"26","author":"Suizu","year":"2006","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2025.218128_bib26","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/mc.20216","article-title":"Targeting carcinogenesis: a role for the prolyl isomerase Pin1?","volume":"45","author":"Lu","year":"2006","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.canlet.2025.218128_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2018.00469","article-title":"Gears-in-motion: the interplay of WW and PPIase domains in PIN1","volume":"8","author":"Lee","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2025.218128_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0127467","article-title":"Pin1 inhibitor juglone exerts anti-oncogenic effects on LNCaP and DU145 cells despite the patterns of gene regulation by Pin1 differing between these cell lines","volume":"10","author":"Kanaoka","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2025.218128_bib29","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.3892\/or.2017.5878","article-title":"Juglone reduces growth and migration of U251 glioblastoma cells and disrupts angiogenesis","volume":"38","author":"Wang","year":"2017","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.canlet.2025.218128_bib30","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/carcin\/bgp027","article-title":"The prolyl isomerase Pin1 interacts with a ribosomal protein S6 kinase to enhance insulin-induced AP-1 activity and cellular transformation","volume":"30","author":"Lee","year":"2009","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.canlet.2025.218128_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2025.156417","article-title":"Juglone induces ferroptotic effect on hepatocellular carcinoma and pan-cancer via the FOSL1-HMOX1 axis","volume":"139","author":"Wang","year":"2025","journal-title":"Phytomedicine"},{"key":"10.1016\/j.canlet.2025.218128_bib32","doi-asserted-by":"crossref","DOI":"10.1007\/s11033-024-09254-6","article-title":"Juglone-ascorbate treatment enhances reactive oxygen species mediated mitochondrial apoptosis in pancreatic cancer","volume":"51","author":"Erkoc-Kaya","year":"2024","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.canlet.2025.218128_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0299921","article-title":"Juglone triggers apoptosis of non-small cell lung cancer through the reactive oxygen species -mediated PI3K\/Akt pathway","volume":"19","author":"Zhong","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2025.218128_bib34","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nm.3839","article-title":"Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer","volume":"21","author":"Wei","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2025.218128_bib35","article-title":"Chemical or genetic Pin1 inhibition exerts potent anticancer activity against hepatocellular carcinoma by blocking multiple cancer-driving pathways","volume":"7","author":"Liao","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2025.218128_bib36","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s12964-023-01194-1","article-title":"ATRA sensitized the response of hepatocellular carcinoma to sorafenib by downregulation of p21-activated kinase 1","volume":"21","author":"Wang","year":"2023","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.canlet.2025.218128_bib37","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1038\/s41467-018-05402-2","article-title":"Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells","volume":"9","author":"Kozono","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2025.218128_bib38","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1182\/blood-2006-04-019588","article-title":"Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells","volume":"109","author":"Leung","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2025.218128_bib39","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15772","article-title":"A covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action","volume":"8","author":"Campaner","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2025.218128_bib40","doi-asserted-by":"crossref","first-page":"15708","DOI":"10.1002\/jcp.28224","article-title":"Virtual screening identifies a PIN1 inhibitor with possible antiovarian cancer effects","volume":"234","author":"Russo Spena","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.canlet.2025.218128_bib41","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.1016\/j.bmcl.2014.07.044","article-title":"Structure-based design of novel human Pin1 inhibitors (III): optimizing affinity beyond the phosphate recognition pocket","volume":"24","author":"Guo","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.canlet.2025.218128_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2023.104718","article-title":"Enhanced activity of a pluronic F127 formulated Pin1 inhibitor for ovarian cancer therapy","author":"Saorin","year":"2023","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.canlet.2025.218128_bib43","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1007\/s13346-024-01559-0","article-title":"Nanocrystals and nanosuspensions: an exploration from classic formulations to advanced drug delivery systems","volume":"14","author":"Rossier","year":"2024","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.canlet.2025.218128_bib44","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.addr.2018.07.011","article-title":"Harnessing albumin as a carrier for cancer therapies","volume":"130","author":"Hoogenboezem","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.canlet.2025.218128_bib45","first-page":"1","article-title":"Current multifunctional albumin-based nanoplatforms for cancer multi-mode therapy","volume":"15","author":"Li","year":"2020","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.canlet.2025.218128_bib46","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3390\/biom9060218","article-title":"Albumin nanovectors in cancer therapy and imaging","volume":"9","author":"Parodi","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.canlet.2025.218128_bib47","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1040-8428(97)00015-2","article-title":"Plasma protein (albumin) catabolism by the tumor itself\u2014implications for tumor metabolism and the genesis of cachexia","volume":"26","author":"Stehle","year":"1997","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.canlet.2025.218128_bib48","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jconrel.2016.12.040","article-title":"Albumin-coated nanocrystals for carrier-free delivery of paclitaxel","volume":"263","author":"Park","year":"2017","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.canlet.2025.218128_bib49","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","article-title":"The toxicity of poisons applied jointly","volume":"26","author":"Bliss","year":"1939","journal-title":"Ann. Appl. Biol."},{"key":"10.1016\/j.canlet.2025.218128_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.121374","article-title":"A carrier free delivery system of a monoacylglycerol lipase hydrophobic inhibitor","volume":"613","author":"Adeel","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.canlet.2025.218128_bib51","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1021\/jp409936v","article-title":"Electrostatic unfolding and interactions of albumin driven by pH changes: a molecular dynamics study","volume":"118","author":"Baler","year":"2014","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.canlet.2025.218128_bib52","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/1097-0126(200006)49:6<623::AID-PI435>3.0.CO;2-8","article-title":"Novel FTIR method for determining the crystallinity of poly(?-caprolactone)","volume":"49","author":"He","year":"2000","journal-title":"Polym. Int."},{"key":"10.1016\/j.canlet.2025.218128_bib53","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.foodres.2018.04.032","article-title":"Infrared spectroscopy as an alternative methodology to evaluate the effect of structural features on the physical-chemical properties of inulins","volume":"109","author":"Romano","year":"2018","journal-title":"Food Res. Int."},{"key":"10.1016\/j.canlet.2025.218128_bib54","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejca.2016.03.005","article-title":"Homologous recombination deficiency and ovarian cancer","volume":"60","author":"Ledermann","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2025.218128_bib55","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000038132","article-title":"Mirvetuximab soravtansine: a breakthrough in targeted therapy for platinum-resistant ovarian cancer","volume":"103","author":"Kokori","year":"2024","journal-title":"Medicine"},{"key":"10.1016\/j.canlet.2025.218128_bib56","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrc.2016.49","article-title":"The isomerase PIN1 controls numerous cancer-driving pathways and is a unique drug target","volume":"16","author":"Zhou","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2025.218128_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2014.00148","article-title":"ShaPINg cell fate upon DNA damage: role of Pin1 isomerase in DNA damage-induced cell death and repair","volume":"4","author":"Polonio-Vallon","year":"2014","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2025.218128_bib58","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1016\/j.cell.2021.07.020","article-title":"Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy","volume":"184","author":"Koikawa","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2025.218128_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106456","article-title":"Targeting prolyl isomerase Pin1 as a promising strategy to overcome resistance to cancer therapies","volume":"184","author":"Wu","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.canlet.2025.218128_bib60","doi-asserted-by":"crossref","first-page":"29771","DOI":"10.18632\/oncotarget.15967","article-title":"Inhibition of the prolyl isomerase Pin1 enhances the ability of sorafenib to induce cell death and inhibit tumor growth in hepatocellular carcinoma","volume":"8","author":"Zheng","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2025.218128_bib61","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s12029-021-00600-6","article-title":"Impact of PIN1 inhibition on tumor progression and chemotherapy sensitivity in colorectal cancer","volume":"53","author":"Gholamzadeh Khoei","year":"2022","journal-title":"J. Gastrointest. Cancer"},{"key":"10.1016\/j.canlet.2025.218128_bib62","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1158\/1535-7163.MCT-19-0656","article-title":"PIN1 inhibition sensitizes chemotherapy in gastric cancer cells by targeting stem cell\u2013like traits and multiple biomarkers","volume":"19","author":"Zhang","year":"2020","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.canlet.2025.218128_bib63","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1007\/s12274-021-3923-9","article-title":"Co-delivery of mitochondrial targeted lonidamine and PIN1 inhibitor ATRA by nanoparticulate systems for synergistic metastasis suppression","volume":"15","author":"Chen","year":"2022","journal-title":"Nano Res."},{"key":"10.1016\/j.canlet.2025.218128_bib64","doi-asserted-by":"crossref","first-page":"3966","DOI":"10.1021\/acs.molpharmaceut.1c00220","article-title":"All-trans retinoic acid and doxorubicin delivery by folic acid modified polymeric micelles for the modulation of Pin1-Mediated DOX-induced breast cancer stemness and metastasis","volume":"18","author":"Liu","year":"2021","journal-title":"Mol. Pharm."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525007001?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525007001?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:02:33Z","timestamp":1766102553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383525007001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":64,"alternative-id":["S0304383525007001"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2025.218128","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanoformulation of a Pin1 inhibitor potentiates the efficacy of liposomal doxorubicin in second-line therapy for ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2025.218128","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"218128"}}